{"nctId":"NCT04140227","briefTitle":"Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)","startDateStruct":{"date":"2020-09-24","type":"ACTUAL"},"conditions":["Dry Eye Disease (DED)"],"count":256,"armGroups":[{"label":"NOV03 4 times daily (QID)","type":"EXPERIMENTAL","interventionNames":["Drug: NOV03"]}],"interventions":[{"name":"NOV03","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed ICF (Informed Consent Form)\n* Subject-reported history of Drye Eye Disease (DED) in both eyes\n* Ability and willingness to follow instructions, including participation in all study assessments and visits\n\nExclusion Criteria:\n\n* Women who are pregnant, nursing or planning pregnancy\n* Unwillingness to submit a blood pregnancy test at screening and the last visit (or early termination visit) if of childbearing potential, or unwillingness to use acceptable means of birth control\n* Clinically significant slit-lamp findings or abnormal lid anatomy at screening\n* Ocular/peri-ocular malignancy\n* History of herpetic keratitis\n* Active ocular allergies or ocular allergies that are expected to be active during the study\n* Ongoing ocular or systemic infection\n* Wear contact lenses within 1 month prior to screening or anticipated use of contact lenses during the study\n* Intra-ocular surgery or ocular laser surgery within the previous 6 months, or have planned ocular and/or lid surgeries over the study period\n* Presence of uncontrolled systemic diseases\n* Presence of known allergy and/or sensitivity to the study drug or saline components\n* Use of any topical steroids treatments, topical cyclosporine, lifitegrast, serum tears or topical anti-glaucoma medication within 2 months prior to screening","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Ocular and Non-ocular Adverse Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":208},"commonTop":["COVID-19","Hypertension","Vitreous detachment","Conjuctivitis allergic","Lacrimation increased"]}}}